| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pivotal data readout example | Bexobrutideg (NX-5948) Relapsed or refractory chronic lymphocytic leukemia (CLL) — pivotal single‑arm study (DAYBreak CLL-201) — registrational intent | Pivotal | — | Subscribe to access the data. | Small Molecules | Oncology | |
Pivotal data readout example | Bexobrutideg (NX-5948) Relapsed or refractory chronic lymphocytic leukemia (CLL) — pivotal single‑arm study (DAYBreak CLL-201) — registrational intent | Pivotal | — | Subscribe to access the data. | Small Molecules | Oncology | |
Pivotal data readout example | Bexobrutideg (NX-5948) Relapsed or refractory chronic lymphocytic leukemia (CLL) — pivotal single‑arm study (DAYBreak CLL-201) — registrational intent | Pivotal | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Nurix Therapeutics, Inc.$23.06
-1.71 (-6.93%)
D 39Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.81 B
EPS
-3.16
P/E Ratio
-
Value Trade
20.79 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.25 M
R&D Expenses
84.14 M
Operating CF
-71.91 M
Total Assets
636.13 M
Total Liabilities
155.24 M
Equity
480.89 M
D/E Ratio
12,345
10.9 %
Week
5.68 %
1 Month
12.11 %
3 Month
14.08 %
6 Month
-30.28 %
5 Year
-3.1 %
All Time
Cash Data
Cash Position
607.69 M
Monthly Burn
23.97 M
Runway
22.5 mo
Burn Trend
SEC Filing
Apr 8, 2026
Overview
Volume
1.55 M
52 Week Range
8.20 - 22.50
% held by Insiders
5.3 %
% held by Institutions
108.39 %
Enterprise Value
1.33 B
Total Shares
103.38 M
Short %
18.2 %
Float Shares
97.80 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nurix Therapeutics, Inc.
380Total events
3Upcoming
44Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 3
Event history 377
Jul 9, 2026
▲Partnership / LicenseNX-5948Corporate
Global collaboration with Roche for bexobrutideg
malignant hematology, immunology, neurologysource ↗
Jun 11, 2026
▲Oral PresentationNX-5948Presentation
Updated Phase 1a/b results for bexobrutideg in R/R CLL/SLL presented at EHA 2026
chronic lymphocytic leukemia/small lymphocytic lymphomasource ↗
Jun 11, 2026
▲Trial InitiationNX-5948Trial
Pivotal Phase 2 trial DAYBreak CLL-201 initiated
relapsed/refractory CLLsource ↗
Jun 8, 2026
▲Partnership / LicenseNX-5948Corporate
Roche and Nurix enter exclusive licensing and collaboration agreement for bexobrutideg
B-cell malignancies, chronic spontaneous urticaria, multiple sclerosissource ↗
Jun 7, 2026
▲Partnership / LicenseNX-5948Corporate
Global collaboration with Roche to co-develop and co-commercialize bexobrutideg
malignant hematology, immunology, neurologysource ↗
Apr 22, 2026
◆Oral PresentationPresentation
Oral presentation: Designing Effective Degrader Therapeutics: What Early Clinical Experience Has Taught Us by Gwenn Hansen
Apr 21, 2026
◆Oral PresentationPresentation
Discovery and characterization of CBL-B intramolecular glue inhibitors that increase T cell activation and suppress tumor growth
cancersource ↗
Apr 21, 2026
◆Poster PresentationNRX-4972PreclinicalPresentation
Poster: NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model
SCLCsource ↗
Drug Pipeline Intelligence
D39
Pipeline Score $129M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 55%
Micro Cap (rank 411 of 911)
Percentile RankNurix Therapeutics, Inc. faces pipeline headwinds (39/100), with $337M risk-adjusted pipeline value, led by NX-5948 in B-cell Lymphoma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NX-5948 Small molecule | B-cell Lymphoma | Phase 3 | NCT07520006 | 42% | $222M | NOT YET_RECRUITING | 770 | VERY_FAST | D (37) | May 1, 2033 | - | LOW May 26, 2026 |
NRIX Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
bexobrutideg Orphan | chronic lymphocytic leukemia (CLL) | Phase 1a/1b | 2026-06-11 | objective response rate: 92.9%; median progression free survival: 22.1 months; objective response rate heavily pretreated: 83%; treatment discontinuations due to adverse events: 5.6% Read More | Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy Read More | |
bexobrutideg Orphan | chronic lymphocytic leukemia (CLL) | Phase 1a/1b | 2026-06-11 | objective response rate: 92.9%; median progression free survival: 22.1 months; objective response rate heavily pretreated: 83%; treatment discontinuations due to adverse events: 5.6% Read More | Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy Read More | |
bexobrutideg Orphan | chronic lymphocytic leukemia (CLL) | Phase 1a/1b | 2026-06-11 | objective response rate: 92.9%; median progression free survival: 22.1 months; objective response rate heavily pretreated: 83%; treatment discontinuations due to adverse events: 5.6% Read More | Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NRIX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NRIX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
NRIX Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Real-Time NRIX Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
NRIX Option Volume & Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NRIX▼ -6.6%on this news
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Nurix Therapeutics reported its Q2 2026 financial results, highlighting a global collaboration with Roche for bexobrutideg, which includes a $700 million upfront payment. The partnership aims to co-develop the drug across multiple indications, including chronic lymphocytic leukemia and autoimmune diseases. Clinical data presented at the European Hematology Association supports its potential as a leading BTK degrader. Despite a net loss of $89.5 million, Nurix remains well-capitalized with significant cash reserves.
Read more →NRIX▲ +11%on this news
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Nurix Therapeutics announced updated Phase 1a/b results for bexobrutideg, showing a high objective response rate of 92.9% in second-line patients with chronic lymphocytic leukemia (CLL) who progressed on a BTK inhibitor. The drug demonstrated a median progression-free survival of 22.1 months in heavily pretreated patients. The findings will be presented at the 2026 EHA Congress, highlighting its potential as a best-in-class treatment.
Read more →NRIX▲ +11%on this newsshared move
Nurix Logo Nurix Therapeutics to Report Updated Phase 1a b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed Refractory CLL SLL and Promising Activity in Earlier Lines of Therapy High obje
Nurix Therapeutics has announced updated results from its Phase 1a b trial for bexobrutideg, reporting a high response rate and promising activity in earlier lines of therapy for chronic lymphocytic leukemia (CLL). The trial demonstrated a 92.9% response rate in patients who had previously progressed on BTK inhibitors, alongside a median progression-free survival of 22.1 months in heavily pretreated patients. The safety profile remains favorable, and the drug appears effective even in complicated cases with high-risk features. These findings will be presented at the 2026 European Hematology Association Congress.
Read more →NRIX▲ +6.8%on this newsshared move
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Read more →NRIX▲ +6.8%on this newsshared move
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Roche has entered a collaboration with Nurix Therapeutics to co-develop bexobrutideg, a novel BTK degrader aimed at treating B-cell malignancies, immunological conditions, and neurological disorders. The agreement includes a significant upfront payment and shared development costs, with Roche leading commercialization efforts. Bexobrutideg is expected to enter Phase 3 trials in summer 2026, potentially offering improved efficacy over existing therapies.
Read more →NRIX▲ +6.8%on this newsshared move
NURIX LOGO Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology Strategic
Nurix Therapeutics has announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, a potential best-in-class oral BTK degrader. This partnership aims to advance treatment options across malignant hematology, immunology, and neurology, with a robust clinical development plan that includes pivotal trials for chronic lymphocytic leukemia (CLL) and Phase 2 trials for conditions like multiple sclerosis. Nurix will receive an upfront payment of $700 million and could earn up to $2.3 billion in total payments over time, sharing profits and losses with Roche in the U.S.
Read more →NRIX▲ +6.8%on this newsshared move
Test
Nurix is pioneering targeted protein degradation to combat diseases, emphasizing the development of Degrader Antibody Conjugates (DACs) for improved treatment precision. Their DEL-AI drug discovery engine aims to advance a diverse pipeline in oncology, immunology, and neurology. The company is committed to delivering safer and more effective patient care.
Read more →NRIXNurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
Read more →NRIXNurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Read more →NRIXNurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
Nurix Therapeutics has announced that an abstract detailing updated efficacy and safety data from the Phase 1a/b trial of its BTK degrader, bexobrutideg (NX-5948), has been accepted for oral presentation at the 2026 European Hematology Association Congress. The presentation is scheduled for June 14, 2026, in Stockholm, Sweden, highlighting its potential in treating chronic lymphocytic leukemia.
Read more →NRIXNurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Read more →NRIXNurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Read more →NRIXNurix logo Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed refrac
Nurix Therapeutics reported its financial results for the first quarter of 2026, highlighting ongoing developments in its pipeline. The company is actively enrolling patients in the Phase 2 DAYBreak CLL-201 trial for bexobrutideg, targeting relapsed refractory chronic lymphocytic leukemia, and preparing for a Phase 3 trial slated for mid-2026. Despite a notable reduction in revenue and a significant net loss compared to the previous year, Nurix maintains a healthy cash position and is exploring additional indications for its investigational drug, all while leveraging strategic partnerships.
Read more →NRIXNurix Therapeutics to Participate in Upcoming Investor Conference
Nurix Therapeutics, a clinical-stage biopharmaceutical company, will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. CEO Arthur Sands will engage in a fireside chat, which will be available for live viewing and archived for 30 days. The company focuses on targeted protein degradation medicines for cancer and autoimmune diseases.
Read more →NRIXNurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
Nurix Therapeutics announced multiple presentations at the AACR 2026 Annual Meeting, showcasing its research pipeline and scientific leadership. Key presentations will focus on therapeutic targets like CBL-B and Aurora kinase A, emphasizing the potential of their orally bioavailable degraders. Chief Scientific Officer Gwenn Hansen will also discuss induced proximity pharmacology, contributing to the understanding of targeted protein degradation.
Read more →NRIXOSU Wexner Medical Center
Nurix is rapidly developing drug candidates focused on targeted protein degradation, aiming to create breakthrough therapies. The company is conducting clinical trials across various locations in the U.S. and internationally. Additionally, Nurix offers expanded access programs for patients with serious conditions to receive investigational drugs not yet approved.
Read more →NRIXTennessee Oncology
Nurix is actively developing targeted protein degradation therapies, including Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127), through clinical trials across multiple sites in the U.S. and internationally. The company emphasizes its commitment to patient care by implementing expanded access programs for investigational drugs. This approach aims to provide potential treatment options for patients with serious or life-threatening conditions.
Read more →NRIXBaylor University Medical Center
Nurix is actively developing drug candidates based on targeted protein degradation, with several clinical trials underway across multiple prestigious institutions in the U.S. and Europe. The company emphasizes its commitment to making these investigational therapies available to patients through expanded access programs. These programs aim to provide patients with serious conditions access to potentially beneficial drugs before they receive regulatory approval.
Read more →NRIXHuntsman Cancer Institute, University of Utah
Nurix is actively working on translating targeted protein degradation into drug candidates, with a focus on Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The company collaborates with various leading cancer treatment centers across the United States and internationally. Additionally, Nurix emphasizes the importance of expanded access programs to provide investigational drugs to patients with serious conditions.
Read more →NRIXSwedish Cancer Institute
Nurix is actively developing drug candidates based on targeted protein degradation, with a focus on clinical trials for therapies like Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The company collaborates with numerous cancer treatment centers across the United States and Europe. Additionally, Nurix is committed to expanding access to investigational drugs for patients with serious conditions.
Read more →NRIXSarah Cannon Research Institute at Florida Cancer Specialists
Nurix is rapidly developing targeted protein degradation therapies, including Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The company is conducting clinical trials at various sites in the US and Europe, aiming to expedite the availability of these therapies. Additionally, Nurix is implementing expanded access programs to provide investigational drugs to patients with serious conditions.
Read more →NRIXNational Institutes of Health Clinical Center
Nurix is actively working on developing drug candidates based on targeted protein degradation, aiming to create breakthrough therapies. The company is conducting multiple clinical trials across various locations in the U.S. and internationally. Additionally, Nurix has established an expanded access policy to provide investigational drugs to patients with serious conditions who cannot participate in trials.
Read more →NRIXMount Sinai Comprehensive Cancer Center
Nurix is actively developing drug candidates based on targeted protein degradation, with clinical trials underway at multiple prestigious institutions across the United States and Europe. The company emphasizes its commitment to making these therapies available quickly through collaborations and expanded access programs. This approach aims to help patients with serious conditions access investigational drugs.
Read more →NRIXSarah Cannon Research Institute at Colorado Blood Cancer Institute
Nurix is actively developing drug candidates focused on targeted protein degradation, with several clinical trials for Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127) taking place across the United States and Europe. The company is committed to expediting the availability of these therapies through expanded access programs for patients with serious conditions. Nurix collaborates with various clinical institutions to enhance patient care.
Read more →NRIXUniversity of California Irvine
Nurix is rapidly developing drug candidates focused on targeted protein degradation, with ongoing clinical trials for Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The company collaborates with various renowned medical institutions across the U.S. and internationally. Additionally, Nurix is committed to expanded access programs to provide investigational drugs to patients with serious conditions.
Read more →NRIXAddenbrookes Cambridge University Hospital
Nurix is actively developing targeted protein degradation therapies, specifically Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127), through extensive clinical trials across various prestigious institutions in the U.S. and Europe. The company emphasizes its commitment to patient care by aiming for rapid regulatory approvals and offering expanded access programs for investigational drugs. This approach aims to provide new therapies for patients with serious conditions.
Read more →NRIXNorthern Centre for Cancer Care
Nurix is actively developing drug candidates based on targeted protein degradation, with a focus on clinical trials for Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The trials are being conducted at multiple renowned cancer centers across the United States and Europe. Nurix aims to expedite the availability of these investigational therapies through expanded access programs for patients with serious conditions.
Read more →NRIXUniversity of Southern California
Nurix is actively developing drug candidates based on targeted protein degradation, with clinical trials underway at multiple prestigious institutions across the United States and Europe. The company emphasizes its commitment to patient care through expanded access programs, allowing patients with serious conditions to potentially receive investigational drugs. This approach aims to expedite the availability of new therapies.
Read more →NRIXUniversity of Colorado School of Medicine
Nurix is actively working on clinical trials for its drug candidates, including Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127), across various prestigious medical institutions. The company emphasizes the importance of enrolling patients in trials and obtaining regulatory approvals to expedite access to new therapies. Additionally, Nurix has an expanded access policy to help patients with serious conditions access investigational drugs.
Read more →NRIXUniversity of North Carolina
Nurix is actively developing drug candidates based on targeted protein degradation, with clinical trials underway at various prestigious institutions across the United States and Europe. Their investigational drugs, including NX-5948 and NX-1607, aim to offer breakthrough therapies for serious diseases. The company is also implementing expanded access programs to provide investigational drugs to patients who cannot participate in clinical trials.
Read more →NRIXUniversity of Oklahoma
Nurix is actively developing drug candidates focused on targeted protein degradation, with several clinical trials underway across various prestigious institutions. The company emphasizes the importance of obtaining regulatory approvals to make their therapies available to patients quickly. Additionally, Nurix has an expanded access policy to provide investigational drugs to patients who cannot participate in clinical trials.
Read more →NRIXUniversity of Virginia
Nurix is rapidly progressing in developing drug candidates focused on targeted protein degradation. The company is conducting clinical trials across various locations in the U.S. and internationally. Additionally, Nurix is committed to making its investigational drugs available to patients through expanded access programs, aiming to address serious medical conditions.
Read more →NRIXUniversity Hospitals Plymouth NHS Trust
Nurix is progressing in the development of targeted protein degradation therapies, specifically Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The company is conducting clinical trials in various locations across the United States and Europe. Additionally, Nurix is committed to making investigational drugs available through expanded access programs for patients with serious conditions.
Read more →NRIXThe Beatson WOS Cancer Center
Nurix is actively developing targeted protein degradation therapies, including Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127), through various clinical trials across multiple locations. The company emphasizes its commitment to patient care by establishing expanded access programs for investigational drugs. This approach aims to expedite the availability of new therapies for patients with serious conditions.
Read more →NRIXSt. James Hospital
Nurix is actively developing drug candidates based on targeted protein degradation, with clinical trials for Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127) underway across numerous sites in the US and Europe. The company emphasizes its commitment to patient care through expanded access programs for investigational drugs. Nurix aims to expedite regulatory approvals to provide new therapies to patients in need.
Read more →NRIXClatterbridge Cancer Center NHS Foundation Trust
Nurix is actively developing drug candidates focused on targeted protein degradation, with clinical trials underway at numerous prestigious institutions across the U.S. and Europe. Their investigational drugs, including Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127), aim to provide breakthrough therapies for serious diseases. The company also emphasizes its commitment to expanded access programs for patients unable to join clinical trials.
Read more →NRIXSt. Bartholomew’s Hospital, Barts NHS Trust
Nurix is actively conducting clinical trials for its drug candidates, including Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127), across various locations in the US and Europe. The company aims to expedite the development of targeted protein degradation therapies. Additionally, Nurix is committed to patient access through expanded access programs for investigational drugs.
Read more →NRIXUniversity Hospital Southampton NHS Foundation Trust
Nurix is actively developing drug candidates focused on targeted protein degradation, with ongoing clinical trials for Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The company collaborates with various hospitals and cancer centers across the United States and Europe to expedite research. Additionally, Nurix offers expanded access programs for patients unable to join clinical trials.
Read more →NRIXRoyal Marsden NHS Foundation Trust
Nurix is actively developing drug candidates based on targeted protein degradation, with ongoing clinical trials for Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127) across various locations. The company emphasizes its commitment to patient care through expanded access programs, allowing patients with serious conditions to access investigational drugs. Collaborations with leading cancer centers enhance their research efforts.
Read more →NRIXRadboud University Medical Center
Nurix is actively developing drug candidates focused on targeted protein degradation, with clinical trials underway across various prestigious institutions in the U.S. and Europe. The company emphasizes its commitment to making these therapies available to patients quickly through expanded access programs. This initiative aims to provide investigational drugs to patients with serious conditions who cannot participate in clinical trials.
Read more →NRIXErasmus MC
Nurix is making significant progress in developing targeted protein degradation therapies, particularly with its drug candidates NX-5948 and NX-2127. The company is collaborating with multiple clinical sites across the U.S. and Europe to conduct clinical trials. Additionally, Nurix is committed to establishing expanded access programs to provide investigational drugs to patients with serious conditions.
Read more →NRIXUniversity Medical Center Utrecht
Nurix is actively developing drug candidates based on targeted protein degradation, with a focus on Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The company is collaborating with various leading medical institutions across the United States and Europe to conduct clinical trials. Additionally, Nurix is committed to making its investigational therapies available to patients through expanded access programs.
Read more →NRIXMemorial Sloan Kettering Cancer Center
Nurix is actively developing drug candidates focused on targeted protein degradation, with clinical trials underway across multiple prestigious cancer centers in the U.S. and internationally. Their investigational drugs, including Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127), aim to provide breakthrough therapies for serious conditions. The company also emphasizes its commitment to expanded access programs for patients unable to participate in trials.
Read more →NRIXDuke University Medical Center
Nurix is actively developing drug candidates based on targeted protein degradation, with clinical trials underway at numerous prestigious institutions across the United States and Europe. The company emphasizes its commitment to patient care through expanded access programs, allowing patients with serious conditions to potentially receive investigational drugs. This approach aims to expedite the availability of new therapies.
Read more →NRIXUniversity of Cincinnati Medical Center
Nurix is actively developing targeted protein degradation therapies, with clinical trials for Bexobrutideg (NX-5948) underway at various sites in the US and Europe. The company emphasizes its commitment to patient access through expanded access programs for investigational drugs. This initiative aims to provide potential treatments for patients with serious conditions who cannot participate in clinical trials.
Read more →NRIXCleveland Clinic
Nurix is actively developing drug candidates based on targeted protein degradation, with several clinical trials underway in the U.S. and internationally. The company emphasizes its commitment to patient care by conducting these trials and pursuing regulatory approvals to make therapies available quickly. Expanded access programs are also in place for patients with serious conditions.
Read more →NRIXMD Anderson Cancer Center
Nurix is rapidly developing drug candidates focused on targeted protein degradation, with clinical trials ongoing at various prestigious institutions. Their investigational drugs, including Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127), aim to provide breakthrough therapies for cancer patients. The company is also committed to expanding access to these investigational drugs for patients in need.
Read more →NRIXMedical College of Wisconsin
Nurix is actively developing drug candidates based on targeted protein degradation, aiming to create breakthrough therapies. The company is conducting clinical trials across various prestigious institutions in the U.S. and internationally. Additionally, Nurix is committed to making its investigational drugs available to patients through expanded access programs.
Read more →NRIXUniversity of California, San Francisco
Nurix is rapidly developing drug candidates focused on targeted protein degradation, with multiple clinical trials underway across various locations in the U.S. and internationally. The company emphasizes its commitment to patient care through expanded access programs, allowing patients with serious conditions to potentially receive investigational drugs. This approach aims to expedite the availability of new therapies.
Read more →NRIXNorthwestern University
Nurix is actively developing drug candidates based on targeted protein degradation, with clinical trials underway across multiple prestigious institutions. The company emphasizes its commitment to making these therapies available to patients quickly through expanded access programs. This approach aims to provide investigational drugs to patients with serious conditions who cannot participate in clinical trials.
Read more →NRIXYale Cancer Center
Nurix is rapidly developing drug candidates focused on targeted protein degradation, with several ongoing clinical trials across various locations. The company emphasizes its commitment to patient care through expanded access programs, allowing patients with serious conditions to potentially receive investigational drugs. This approach aims to facilitate quicker access to innovative therapies.
Read more →NRIXUniversity of Miami
Nurix is actively working on developing drug candidates through targeted protein degradation. Their investigational drug, NX-5948, is being studied across various clinical sites in the U.S. and internationally. The company emphasizes its commitment to making these therapies available to patients quickly, including through expanded access programs for those unable to participate in clinical trials.
Read more →NRIXWinship Cancer Institute of Emory University
Nurix is actively developing drug candidates based on targeted protein degradation, aiming to create breakthrough therapies. The company is conducting clinical trials across multiple prestigious institutions in the U.S. and internationally. Their commitment to patient care includes expanded access programs for investigational drugs, ensuring patients with serious conditions can benefit from new therapies.
Read more →NRIXCity of Hope
Nurix is actively conducting clinical trials for its investigational drugs, including NX-5948 and NX-2127, across multiple locations in the United States and Europe. The company aims to develop breakthrough therapies through targeted protein degradation. Additionally, Nurix is committed to making its investigational medicines available to patients through expanded access programs.
Read more →NRIXOxford University Hospitals NHS Foundation Trust
Nurix is making significant progress in developing targeted protein degradation therapies, including Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The company is collaborating with various clinical sites across the United States and Europe to conduct clinical trials. Additionally, Nurix is committed to establishing expanded access programs to provide investigational drugs to patients with serious conditions.
Read more →NRIXThe Christie NHS Foundation Trust
Nurix is actively developing drug candidates based on targeted protein degradation, with a focus on clinical trials for therapies like Bexobrutideg (NX-5948) and Zelebrudomide (NX-2127). The company collaborates with numerous healthcare institutions across the United States and Europe to expedite the availability of these therapies. Additionally, Nurix is committed to expanded access programs to help patients with serious conditions access investigational drugs.
Read more →NRIXNurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
Nurix Therapeutics reported its fourth quarter and fiscal year 2025 financial results, highlighting the initiation of the DAYBreak™ program for bexobrutideg in relapsed/refractory CLL. The company presented compelling Phase 1 results, showing an 83% overall response rate. Despite a net loss of $78.2 million, Nurix remains well-capitalized with $592.9 million in cash. The report also noted advancements in their IRAK4 degrader program and other clinical initiatives.
Read more →NRIX▼ -7.9%on this newsshared move
Nurix logo Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed refractory
Nurix Therapeutics reported its financial results for Q4 and FY 2025, highlighting the initiation of the DAYBreak registrational program for bexobrutideg in relapsed refractory chronic lymphocytic leukemia (CLL). The company presented promising Phase 1 data at the ASH 2025 conference, showcasing an 83% objective response rate and a progression-free survival of 22.1 months. Nurix has reinforced its financial position with $592.9 million in resources, supporting the development of bexobrutideg and other therapeutic candidates. Encouraging preclinical data for IRAK4 degrader GS-6791 was also provided, demonstrating progress across multiple clinical programs.
Read more →NRIXNurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases Execute a pivotal program for potential best-in-class
Nurix Therapeutics has laid out its strategic goals for 2026, focusing on the clinical advancement of bexobrutideg, a potentially best-in-class BTK degrader for relapsed refractory chronic lymphocytic leukemia (CLL). The company aims to execute pivotal clinical trials and expand indications for bexobrutideg into autoimmune diseases. Additionally, Nurix highlighted recent achievements, including impressive clinical data and a strong financial position, which will facilitate its pipeline expansion and development initiatives.
Read more →NRIXNurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be led by CEO Arthur T. Sands and will be accessible via a live webcast. Nurix is focused on developing targeted protein degradation medicines for oncology and autoimmune diseases, with a robust pipeline of drug candidates.
Read more →NRIX▲ +18.7%on this news
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
Nurix Therapeutics presented promising data from its Phase 1 trial of bexobrutideg (NX-5948) for Waldenström macroglobulinemia at the ASH Annual Meeting. The trial showed a 75% objective response rate among heavily pre-treated patients, with no dose-limiting toxicities reported. The drug was well tolerated, indicating its potential as a new therapeutic option.
Read more →NRIX▲ +18.7%on this newsshared move
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
Nurix Therapeutics presented promising Phase 1 data for bexobrutideg at the ASH Annual Meeting. The study showed an 83% objective response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a median progression-free survival of 22.1 months. The drug was well tolerated, and a Phase 2 trial is currently enrolling patients. The findings support the advancement of bexobrutideg as a potential treatment option.
Read more →NRIXNurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
Nurix Therapeutics will host a live webcast on December 8, 2025, to discuss new data from its Phase 1a/1b trial of bexobrutideg (NX-5948), a BTK degrader. The event will feature presentations from key clinical investigators and company executives, highlighting the drug's potential in treating relapsed/refractory chronic lymphocytic leukemia and Waldenström macroglobulinemia. The webcast aims to provide updates on Nurix's clinical development strategy and corporate progress.
Read more →NRIXNurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nurix Therapeutics, Inc. will be participating in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. CEO Arthur T. Sands and CFO Hans van Houte will feature in a fireside chat set to explore the company's developments in targeted protein degradation for oncology and autoimmune diseases. The chat will be webcast live and available for 30 days post-event, highlighting Nurix's clinical advancements and efforts in drug design.
Read more →NRIXNurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Nurix Therapeutics has appointed Roger Dansey, M.D., to its board of directors. Dr. Dansey brings over two decades of experience in drug development and oncology, previously serving in leadership roles at Pfizer and Seagen. His expertise is expected to guide Nurix in accelerating pivotal trials for its lead asset, bexobrutideg, in chronic lymphocytic leukemia.
Read more →NRIXNurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
Nurix Therapeutics presented new data from its Phase 1 trial of NX-1607 at the SITC 2025 Annual Meeting. The findings indicate that NX-1607, an oral CBL-B inhibitor, activates T cells and remodels the tumor microenvironment in patients with advanced solid tumors. Notably, a patient with metastatic castration-resistant prostate cancer achieved stable disease during treatment. These results support the potential of NX-1607 as a novel immune-oncology therapy.
Read more →NRIXNurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics announced that updated clinical data from its NX-5948-301 Phase 1a/1b trial will be presented at the upcoming 67th ASH Annual Meeting. The presentations will include new findings on Bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia and updated results for Waldenström macroglobulinemia. Additionally, insights into resistance mechanisms to BTK therapies will be shared.
Read more →NRIX▲ +8%on this newsshared move
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
Nurix Therapeutics has successfully closed a $250 million registered offering of common stock, selling 24,485,799 shares at $10.21 each. The funds will primarily support the clinical development of its drug candidates, including bexobrutideg for chronic lymphocytic leukemia and potential autoimmune indications. The offering was well-received, with participation from various investors.
Read more →NRIXNurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
Nurix Therapeutics has launched the DAYBreak pivotal study for bexobrutideg, targeting relapsed or refractory chronic lymphocytic leukemia. The study will evaluate a 600 mg daily dose, following regulatory approval. Preclinical data suggests a promising profile for bexobrutideg, with plans for a Phase 3 trial in 2026 to confirm its efficacy against existing treatments.
Read more →NRIXNurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
Nurix Therapeutics has announced a registered offering of 24,485,799 shares of common stock priced at $10.21 per share, aiming to raise $250 million. The proceeds from the offering will be primarily used to fund clinical development of its drug candidates, including bexobrutideg for chronic lymphocytic leukemia, and to support research and development efforts. The closing of the offering is expected to occur on October 23, 2025, pending customary conditions. The offering has attracted participation from various investors, indicating a solid backing for Nurix's ongoing projects.
Read more →NRIX▲ +5.6%on this newsshared move
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
Nurix Therapeutics presented new clinical data for NX-1607, a first-in-class oral CBL-B inhibitor, at the ESMO Congress. The Phase 1a study showed promising anti-tumor activity in heavily pretreated patients with various solid tumors, including reductions in tumor biomarkers and stable disease. The drug demonstrated a favorable safety profile, supporting further development in advanced solid tumors.
Read more →NRIX▼ -10.1%on this news
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Nurix Therapeutics reported its financial results for Q3 2025, highlighting plans to initiate pivotal trials for bexobrutideg in relapsed/refractory CLL by the end of the year. The company also presented promising preclinical data for GS-6791 at EADV 2025. Despite a significant net loss and decreased revenue, Nurix remains well-capitalized with $428.8 million in cash.
Read more →NRIX▲ +8.8%on this newsshared move
Nurix logo Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed ref
Nurix Therapeutics reported its financial results for Q3 2025, revealing plans to initiate pivotal trials for bexobrutideg in relapsed refractory chronic lymphocytic leukemia (CLL) in H2 2025. The company presented promising preclinical data for GS-6791 at a recent congress, demonstrating potential efficacy in treating autoimmune diseases. Despite a decrease in revenue and an increase in net loss compared to the previous year, Nurix maintains a strong financial position with $428.8 million in cash and marketable securities. These developments position Nurix to advance its innovative drug candidates and collaborations.
Read more →NRIXNurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Nurix Therapeutics presented preclinical data on GS-6791, a novel IRAK4 degrader, at the EADV Congress. The data indicate that GS-6791 effectively inhibits IL-1 and IL-36 responses and shows promise in reducing symptoms of atopic dermatitis in preclinical models. The findings support the drug's advancement into clinical trials, highlighting its potential in treating inflammatory diseases.
Read more →NRIX▲ +7.9%on this news
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Read more →NRIX▲ +7.9%on this news
Nurix logo Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profi
Nurix Therapeutics reported its second-quarter 2025 financial results, highlighting significant progress in its clinical programs. The company provided updated data on bexobrutideg (NX-5948) showing strong efficacy in chronic lymphocytic leukemia (CLL) patients. Additionally, Sanofi extended its license for the STAT6 program, generating a $15 million fee for Nurix, while the FDA cleared an IND application for the IRAK4 degrader GS-6791. Overall, Nurix appears to be advancing well in its strategic collaborations and product developments.
Read more →NRIXNurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics, Inc. has reported the granting of inducement awards to seventeen new employees as part of its 2024 Equity Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The awards include stock options for 97,400 shares and restricted stock units for 66,750 shares, designed to attract and retain talent within the company. These inducements underscore Nurix's commitment to growth and its innovative approach in the biopharmaceutical sector, focusing on targeted protein degradation medicines for various diseases.
Read more →NRIX▼ -5.3%on this newsshared move
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
Read more →NRIXNurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
Nurix Therapeutics will host a webcast conference call on June 12, 2025, to discuss data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948). This treatment, aimed at relapsed refractory B cell malignancies, presents new findings that will be shared during the European Hematology Association Congress in Milan, Italy. The updates will focus on its clinical activity and safety profile, which is being assessed in multiple studies related to CLL and Waldenström macroglobulinemia.
Read more →NRIX▲ +14.2%on this news
Sanofi Exercises License Extension Option to Nurix's STAT6 Program
Sanofi Exercises License Extension Option to Nurix's STAT6 Program
Read more →NRIXNurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
Nurix Therapeutics, Inc. announced its participation in the Jefferies Global Healthcare Conference, where CEO Arthur T. Sands and CFO Hans van Houte will engage in a fireside chat. The event is scheduled for June 4, 2025, and will be webcast live, providing broad access to stakeholders. Nurix specializes in developing targeted protein degradation medicines, advancing solutions for cancer and inflammatory diseases through its clinical and preclinical pipelines. This participation highlights Nurix's commitment to transparent investor relations and innovative healthcare advancements.
Read more →NRIXNurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
Nurix Therapeutics, Inc. will participate in the RBC Capital Markets Global Healthcare Conference on May 21, 2025. The company's CFO and CBO will hold a fireside chat to discuss their clinical-stage biopharmaceutical efforts in targeted protein degradation medicines. The event will be webcasting live and will be accessible through Nurix's website. Nurix is focused on advancing treatment options for cancer and inflammatory diseases and has partnerships with major pharmaceutical companies.
Read more →NRIXNurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
Nurix Therapeutics has announced the upcoming presentations of clinical data for its investigational drug bexobrutideg (NX-5948) at two major conferences: the EHA 2025 Congress and the 18th International Conference on Malignant Lymphoma. These presentations will highlight data from an ongoing Phase 1a/b clinical trial for patients with relapsed/refractory chronic lymphocytic leukemia and Waldenström macroglobulinemia. The findings suggest significant clinical efficacy and an acceptable safety profile for bexobrutideg.
Read more →NRIXNurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs
Read more →NRIXNurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Read more →NRIXNurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
Nurix Therapeutics has received FDA clearance for its IND application for GS-6791/NX-0479, a novel IRAK4 degrader aimed at treating inflammatory conditions. Gilead Sciences, Nurix's collaboration partner, is set to commence Phase 1 clinical trials in healthy volunteers by Q2 2025. This development marks a significant milestone as Nurix secures a $5 million milestone payment and remains eligible for substantial future payments totaling $420 million. The drug's potential applications include treating diseases like rheumatoid arthritis and atopic dermatitis, showcasing Nurix's commitment to advanced targeted protein degradation therapies.
Read more →NRIXNurix logo Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update NX-5948 assigned the nonproprietary name " bexobrutideg " U.S. FDA Orphan Drug Designation granted to bexobrutide
Nurix Therapeutics reported its financial results for the first quarter of 2025, highlighting significant achievements including FDA Orphan Drug Designation for its lead drug bexobrutideg. The company announced a total revenue of $18.5 million, an increase from the previous quarter, and strengthened its executive team with new appointments. Nurix's financial situation is robust, with $549.7 million in cash and marketable securities. The firm is on track to initiate pivotal trials for bexobrutideg in the upcoming year, showcasing ongoing progress in its pipeline.
Read more →NRIXNurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Read more →NRIX▲ +8.7%on this news
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
Read more →NRIX▼ -5.7%on this news
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Read more →NRIX▼ -9.3%on this newsshared move
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors
Nurix Therapeutics has appointed Dr. Roy D. Baynes to its board of directors. Dr. Baynes, known for his extensive experience in hematology and oncology, has previously held significant roles at major pharmaceutical firms including Merck and Gilead Sciences. His expertise is expected to enhance Nurix's clinical pipeline, particularly in oncology and autoimmune indications, as the company focuses on the development of targeted protein degradation medicines. The appointment follows Dr. Baynes' prior involvement as a clinical advisor to the company.
Read more →NRIXNurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Read more →NRIXNurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relap
Nurix Therapeutics has reported strong financial results for Q4 and fiscal year 2024, alongside a corporate update highlighting significant clinical trial progress. The company's investigational drug NX-5948 has demonstrated a promising objective response rate of 75.5% in patients with relapsed refractory CLL at a recent conference. Additionally, NX-5948 has received Fast Track and PRIME designations for further development, reflecting its potential in treating serious hematological diseases. Nurix also announced the appointment of John Northcott as Chief Commercial Officer, enhancing its leadership team as it prepares for pivotal clinical programs.
Read more →NRIXNurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Nurix Therapeutics has appointed John Northcott as Chief Commercial Officer to lead the company's commercial strategy ahead of its pivotal clinical program for NX-5948, a novel treatment for chronic lymphocytic leukemia and other B-cell malignancies. Northcott brings over 20 years of experience, having successfully commercialized the first marketed BTK inhibitor, ibrutinib. The investigational drug NX-5948 is currently being evaluated in a Phase 1 clinical trial, showing promising response rates in challenging patient populations.
Read more →NRIXNurix Logo Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases Initiate a suite of clinical trials in 2025 intended to support global registratio
Nurix Therapeutics has set strategic goals for 2025, focusing on advancing clinical trials for NX-5948 aimed at treating chronic lymphocytic leukemia and other conditions. The company plans to initiate multiple clinical trials and expand its drug development portfolio, supported by a robust financial position. Recent achievements include receiving Fast Track Designation from the FDA and positive clinical data published at major oncology meetings. Additionally, Nurix is investing in its AI-driven discovery platform to enhance its research capabilities.
Read more →NRIXNurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
Read more →NRIXNurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Read more →NRIXNurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia
Read more →NRIXNurix logo Nurix Therapeutics Presents New Positive Data from Phase 1a 1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66 th American Society of Hematology Annual Meeting Durable responses are rapid a
Nurix Therapeutics announced positive data from its Phase 1a/1b clinical trial for NX-5948 in treating relapsed or refractory chronic lymphocytic leukemia (CLL). The trial reported an initial 75.5% Objective Response Rate that increased to 84.2% after further assessments, demonstrating rapid and durable responses. The treatment showed a favorable safety profile, particularly in a heavily pre-treated patient population with challenging clinical features. The company plans to continue patient enrollment and initiate pivotal trials in 2025.
Read more →NRIXNurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
Nurix Therapeutics has presented new positive clinical data for NX-5948, a treatment for relapsed or refractory chronic lymphocytic leukemia (CLL/SLL), at the 66th American Society of Hematology Annual Meeting. The trial reported an objective response rate (ORR) of 75.5%, which improved to 84.2% with longer treatment durations. The safety profile of NX-5948 was found to be favorable, with no significant adverse effects. The findings highlight the potential of NX-5948 in addressing challenging patient populations with poor prognostic features.
Read more →NRIXNurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
Read more →NRIXNurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nurix Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Piper Sandler 36th Annual Healthcare Conference. During the event, CEO Arthur T. Sands will provide a corporate update, highlighting the company's developments in targeted protein modulation drugs. This conference will enable the company to present its innovative approaches to treat cancer and inflammatory diseases. The event will be accessible via a live webcast and will remain archived for 30 days post-event.
Read more →NRIXNurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
Nurix Therapeutics has announced that its drug NX-5948 has received PRIME designation from the European Medicines Agency. This designation highlights the drug's potential to address unmet needs in the treatment of relapsed or refractory chronic lymphocytic leukemia. Early clinical data demonstrates promising safety and efficacy, with plans for pivotal trials starting in 2025. The PRIME initiative aims to enhance support for promising medicines and accelerate their development and evaluation.
Read more →NRIXNurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
Read more →NRIXNX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Nurix's NX-5948, a clinical-stage BTK degrader, has shown significant promise by achieving deep suppression of BCR, TLR, and FcR signaling in immune cells. The compound demonstrated efficacy in preclinical models targeting arthritis and other inflammatory diseases, suggesting its potential as a breakthrough therapy in these areas.
Read more →NRIX▼ -14.7%on this newsshared move
IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Nurix has reported that its IRAK4 degrader GS-6791 effectively inhibits TLR and IL-1R-driven inflammatory signaling. This compound has shown the ability to ameliorate disease symptoms in a preclinical model of arthritis. The findings suggest a potential new avenue for treating autoimmune diseases.
Read more →NRIXNurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics, Inc. has announced its participation in the 66th American Society of Hematology Annual Meeting, where it will present data on its BTK degrader programs, NX-5948 and NX-2127. These presentations will include oral and poster formats, highlighting research on their efficacy and mechanisms in treating chronic lymphocytic leukemia and other B-cell malignancies. The annual meeting is scheduled for December 7-10, 2024, in San Diego, California. This event represents an opportunity for Nurix to showcase its advancements in targeted protein modulation therapies.
Read more →NRIXClinical Activity of NX-5948: A First-in-Class BTK Degrader
Nurix is focused on developing innovative therapies targeting cancer and autoimmune diseases. The article highlights their commitment to advancing a multi-modal portfolio, including the first-in-class BTK degrader NX-5948. However, specific clinical activity details or outcomes related to NX-5948 are not provided.
Read more →NRIXAn Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader for the Treatment of Primary and Inhibitor-Resistant Solid Tumors
Nurix is advancing its portfolio aimed at developing therapies for cancer and autoimmune diseases. The company emphasizes the importance of translating scientific insights into effective treatments. Their focus includes a novel BRAF degrader that shows promise for treating solid tumors, particularly those resistant to existing inhibitors.
Read more →NRIXNurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
Nurix Therapeutics, Inc. has announced its participation in the 7th Annual TPD & Induced Proximity Summit, set to be held from October 28-31, 2024, in Boston. The company will present new preclinical data on its brain-penetrant B-Raf degrader program and clinical updates on the NX-5948 BTK degrader program. Nurix's leadership will also engage in multiple panel discussions, highlighting their role in advancing targeted protein degradation therapies. This reveals Nurix's commitment to sharing its innovative research and engaging with industry experts.
Read more →NRIXNX-5948: BTK Degrader with Activity in Lymphoid Malignancies
Nurix is focused on developing innovative therapies, particularly in the field of cancer and autoimmune diseases. Their approach involves leveraging novel scientific insights to enhance their portfolio of assets. The article highlights their commitment to protein degradation resources, although specific details about NX-5948's efficacy or clinical progress are not provided.
Read more →NRIXNurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
Nurix Therapeutics has presented promising data from its ongoing Phase 1a/1b clinical trial for NX-5948, a BTK degrader aimed at treating patients with relapsed/refractory Waldenstrom's macroglobulinemia. The trial showed a 77.8% objective response rate among evaluable patients, with responses deepening over time and some patients remaining on treatment for over a year. The drug also has a tolerable safety profile and the potential advantage of brain penetration, particularly beneficial for patients with central nervous system involvement. These results were shared at the 12th International Workshop on Waldenstrom's Macroglobulinemia in Prague.
Read more →NRIXNurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur
Nurix Therapeutics has appointed Anil Kapur to its board of directors, effective October 15, 2024. Kapur brings over 25 years of experience in pharmaceuticals, with a strong track record of launching successful drugs, particularly in hematology and oncology. His expertise is expected to support Nurix's strategy to advance their drug NX-5948 into pivotal clinical trials in 2025. This appointment comes during a critical phase of the company’s development and underscores the potential of Nurix's drug pipeline to transform treatment for B cell malignancies.
Read more →NRIXNurix Therapeutics Appoints Anil Kapur to its Board of Directors
Nurix Therapeutics Appoints Anil Kapur to its Board of Directors
Read more →NRIXWillis H. Navarro, M.D
Willis H. Navarro, M.D., has been appointed Vice President of Clinical Development at Nurix as of September 2024. With over 15 years of experience in drug development, he has previously held leadership roles at various biopharma companies and served as an academic physician at UCSF. He is currently a Clinical Professor of Medicine at the University of Arizona Cancer Center.
Read more →NRIX▲ +8.1%on this newsshared move
Nurix logo Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast
Nurix Therapeutics reported its financial results for the third quarter of fiscal 2024, highlighting significant advancements in their clinical pipeline. The company has initiated a Phase 1b dose expansion for NX-5948 targeting chronic lymphocytic leukemia and other lymphoma patient populations. Additionally, enrollment for the NX-2127 trial has been reinitiated following the lifting of a clinical hold by the FDA. Nurix remains financially robust with $457.5 million available for continued development, indicating a focus on future clinical data and pivotal studies in 2025.
Read more →NRIX▲ +8.1%on this newsshared move
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Read more →NRIXNurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
Nurix Therapeutics announced that it will present preclinical data for its drugs NX-5948 and GS-6791/NX-0479 at ACR Convergence 2024, the annual meeting of the American College of Rheumatology. NX-5948 is currently in Phase 1b development aimed at treating B-cell malignancies, while GS-6791 is a collaboration with Gilead Sciences intended for autoimmune diseases. Both presentations are scheduled during the conference taking place from November 14-19, 2024. These developments underscore Nurix's commitment to advancing targeted protein modulation therapies.
Read more →NRIXScreening DNA Binding Proteins with DNA Encoded Libraries
Nurix is committed to developing innovative therapies by leveraging scientific insights. The company is advancing a diverse portfolio of assets aimed at combating cancer and autoimmune diseases. Their focus on protein degradation resources highlights their dedication to addressing significant health challenges.
Read more →NRIXThe Evolving Chemical Space of Bi-functional Degraders Targeting the CNS
Nurix is focused on translating scientific insights into innovative therapies, particularly in the areas of cancer and autoimmune diseases. The company is advancing its multi-modal portfolio, which includes both wholly owned and partnered assets. They also provide resources related to protein degradation.
Read more →NRIXRational Discovery of a Small Molecule Intramolecular Glue Inhibitor of CBL-B that Enhances T-cell Function
Nurix is focused on developing innovative therapies targeting cancer and autoimmune diseases. Their recent work involves a small molecule intramolecular glue inhibitor of CBL-B, which is designed to enhance T-cell function. The company aims to leverage novel scientific insights to advance its multi-modal portfolio.
Read more →NRIXNurix Therapeutics Announces Presentations at Discovery on Target Conference
Nurix Therapeutics Announces Presentations at Discovery on Target Conference
Read more →NRIXAccelerating Targeted Protein Degrader Discovery with Automated and Integrated Direct-To-Biology Screening
Nurix is focused on developing innovative therapies through targeted protein degradation. The company is advancing its multi-modal portfolio to combat cancer and autoimmune diseases. Their approach includes automated and integrated direct-to-biology screening, which may enhance drug discovery processes.
Read more →NRIXTargeted Protein Degraders As Next Generation Antibody Payloads
Nurix is committed to translating novel scientific insights into innovative therapies aimed at combating cancer and autoimmune diseases. The company is advancing its multi-modal portfolio, which includes both wholly owned and partnered assets. This approach highlights their focus on targeted protein degraders as potential next-generation antibody payloads.
Read more →NRIXNurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Nurix Therapeutics, a clinical stage biopharmaceutical company, will participate in the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit on September 9-10, 2024. Dr. Gwenn M. Hansen, the company's chief scientific officer, will present an update on the Degrader-Antibody Conjugate (DAC) platform. This presentation will focus on targeted protein degraders as next-generation antibody payloads. The company's innovative approach aims to treat cancer and inflammatory diseases through modulation of cellular proteins.
Read more →NRIXUsing DEL for Targeted Protein Modulation
Nurix is dedicated to developing innovative therapies by leveraging novel scientific insights. The company aims to enhance its portfolio of assets to effectively combat cancer and autoimmune diseases. Their focus on protein degradation resources highlights their commitment to advancing targeted protein modulation.
Read more →NRIXA Rapid Matrix Approach for the Discovery of Potent IRAK4 Targeted Protein Degraders
Nurix is focused on developing innovative therapies targeting cancer and autoimmune diseases through protein degradation. The company emphasizes its commitment to translating scientific insights into effective treatments. The article highlights their multi-modal portfolio, which includes both wholly owned and partnered assets.
Read more →NRIX▲ +8.8%on this news
Nurix logo Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Presented positive clinical data at the European Hematology Association Congress supporting a potential b
Nurix Therapeutics reported strong financial results for Q2 of fiscal 2024, highlighting positive clinical data for NX-5948 presented at the EHA2024 Congress. The company appointed new C-suite executives, which bolsters its clinical operations ahead of pivotal trials planned for 2025. Furthermore, Nurix's financial health is robust, with a substantial cash balance aimed at accelerating development across its portfolio. Overall, the company is positioned well for upcoming phases of clinical trials and potential collaborations.
Read more →NRIX▲ +8.8%on this news
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Nurix Therapeutics has reported strong financial results for Q2 fiscal 2024, ending with $452.5 million in cash. The company presented promising clinical data supporting NX-5948's use in treating chronic lymphocytic leukemia at the European Hematology Association Congress. Additionally, Nurix strengthened its leadership team with new appointments and highlighted plans to initiate pivotal trials for NX-5948 in 2025. Collaborations with major pharmaceutical companies continue to progress, contributing to the company's growth.
Read more →NRIX▲ +5.3%on this newsshared move
Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
Nurix Therapeutics announced its participation in the UBS Virtual Targeted Protein Degradation Day, scheduled for July 15, 2024. Arthur T. Sands, M.D., Ph.D., CEO of Nurix, will engage in a fireside chat during the event, which is expected to spotlight the company's advancements in targeted protein modulation drugs. Nurix is a clinical-stage biopharmaceutical company focusing on innovative treatments for cancer and inflammatory diseases, utilizing its proprietary DELigase discovery platform. The event will be accessible via webcast, with an archived version available for 30 days post-event.
Read more →NRIXLatest Results from an Ongoing First-in-Human Phase 1a/b Study of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory CLL and Other B-cell Malignancies
Nurix is conducting a Phase 1a/b study of NX-5948, a selective BTK degrader, targeting patients with relapsed/refractory CLL and other B-cell malignancies. The study aims to explore the drug's efficacy and safety profile. This research reflects Nurix's commitment to developing novel therapies for challenging diseases.
Read more →NRIXNurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
Nurix Therapeutics (NRIX) presented positive clinical data for NX-5948 during the EHA2024 congress, highlighting a 69.2% objective response rate in patients with relapsed refractory chronic lymphocytic leukemia (CLL). The treatment demonstrated rapid clinical responses that deepened over time, prompting plans to advance to pivotal trials in 2025. The findings suggest NX-5948 could be a significant treatment option for patients with difficult-to-treat CLL cases, especially those with BTK inhibitor resistance mutations.
Read more →NRIXNurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
Read more →NRIXAutomated Method Development for High Throughput Purification at Nurix Therapeutics
Nurix Therapeutics is committed to developing innovative therapies by leveraging novel scientific insights. The company is advancing its multi-modal portfolio, which includes both wholly owned and partnered assets, aimed at addressing cancer and autoimmune diseases. Their resources focus on protein degradation, highlighting their dedication to high throughput purification methods.
Read more →NRIXNurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
Nurix Therapeutics has appointed Dr. Paula G. O’Connor as Chief Medical Officer and Dr. Pasit Phiasivongsa as Chief Technical Officer. Both appointees bring extensive experience in drug development, with Dr. O'Connor focusing on cancer therapies and Dr. Phiasivongsa enhancing technical operations. Their appointments are aimed at advancing Nurix's drug pipeline, particularly the NX-5948 program, which is currently in clinical trials for B cell malignancies. The leadership changes reflect Nurix's strategy to emphasize collaboration and efficiency in drug development.
Read more →NRIXNurix Therapeutics Announces Board Chair Transition
Nurix Therapeutics has announced the transition of its board chair from David L. Lacey to Julia P. Gregory following the annual meeting of stockholders. Dr. Lacey, who has been instrumental in the company’s development since 2016, will remain on the board and continue to lead its Compensation Committee. Ms. Gregory brings extensive experience in biotechnology financial strategy and management to her new role as chair, promising to advance the company’s innovative drug programs toward commercialization. The leadership change is expected to build on Nurix's momentum in drug discovery and development.
Read more →NRIX▲ +7.2%on this news· ran to +19% by day 3
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
Nurix Therapeutics announced an upcoming oral presentation at the European Hematology Association Congress (EHA2024) showcasing new clinical data for NX-5948. The presentation will highlight findings from a Phase 1a/b study involving heavily pretreated patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. Key data indicate a 70% overall response rate among 10 evaluable CLL patients, with improvements observed over time. Additional data, including higher dose levels, will be presented during the congress scheduled from June 13 to 16, 2024.
Read more →NRIX▲ +7.1%on this news
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
Nurix Therapeutics announced its participation in the RBC Capital Markets Global Healthcare Conference, scheduled for May 14, 2024. The chat will feature Arthur T. Sands, the company's CEO, and will focus on their advancements in targeted protein modulation therapies. The event will be webcast live, allowing a wider audience to engage with Nurix's innovative drug development approach. This participation signals the company's ongoing commitment to advancing treatments for cancer and inflammatory diseases.
Read more →NRIXInitial finding from a first-in-human Phase 1a/b trial of NX-5948, a selective BTK degrader
Nurix is focused on developing innovative therapies for cancer and autoimmune diseases. The article mentions a first-in-human Phase 1a/b trial of NX-5948, a selective BTK degrader, but does not provide specific findings or results from the trial.
Read more →NRIX▼ -5.9%on this news
Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies
Nurix has reported initial findings from a Phase 1a/b trial of NX-5948, a selective Bruton’s tyrosine kinase degrader. This trial targets patients with relapsed or refractory B-cell malignancies, showcasing a novel therapeutic approach. The company aims to leverage these findings to enhance treatment options for cancer and autoimmune diseases.
Read more →NRIX▼ -5.2%on this newsshared move
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nurix Therapeutics, Inc. announced the successful closing of its public offering, selling 11,916,667 shares at $15.00 each, which includes 1,750,000 shares from the underwriters' exercised option. The offering generated around $188.6 million in net proceeds to fund the company's clinical stage pipeline. J.P. Morgan Securities, Piper Sandler, and Stifel served as joint book-running managers for this offering. It was conducted under a previously filed shelf registration statement with the SEC.
Read more →NRIX▲ +9.7%on this newsshared move
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
Nurix Therapeutics announced the pricing of its upsized public offering for 10,166,667 shares at $15.00 per share, totaling $175.0 million in gross proceeds. The offering also includes pre-funded warrants to purchase additional shares. Proceeds will be utilized for clinical development, research, and working capital. The offering is set to close by April 16, 2024, pending customary conditions.
Read more →NRIX▲ +9.7%on this newsshared move
Nurix Therapeutics Announces Proposed Public Offering
Nurix Therapeutics has announced a proposed public offering of $125 million in common stock, with the option for certain investors to purchase pre-funded warrants. The funds raised will primarily support the clinical development of its drug candidates and expand research efforts. The offering is contingent on market conditions and may include an additional share purchase option for underwriters. Nurix's innovative approach targets protein modulation for cancer and inflammatory diseases, emphasizing its ongoing commitment to advancing its pipeline.
Read more →NRIX▼ -10.2%on this newsshared move
Nurix logo Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi
Nurix Therapeutics announced its first quarter fiscal 2024 financial results, highlighting extensions of collaborations with Gilead Sciences and Sanofi. The company presented clinical data showing promising responses from its drug NX-5948 in patients with CNS lymphoma and CLL. However, Nurix also reported a net loss of $41.5 million, reflecting ongoing financial challenges as it invests heavily in research and clinical trials. The firm remains optimistic, focusing on advancing its clinical pipeline and engaging in innovative partnerships.
Read more →NRIX▼ -10.2%on this newsshared move
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Nurix Therapeutics has reported strong financial results for the first quarter of fiscal 2024, with revenue rising to $16.6 million. The company expanded collaborations with Gilead and Sanofi, focusing on key inflammation targets and novel cancer treatments. Positive clinical data for NX-5948 was presented, demonstrating significant responses in patients with central nervous system cancers. However, despite these advancements, Nurix incurred a net loss of $41.5 million, reflecting increased research and development costs.
Read more →NRIX▲ +26.7%on this newsshared move
NX-5948, a brain-penetrant BTK degrader with clinical activity in B-cell malignancies including CNS lymphoma
Nurix is advancing NX-5948, a brain-penetrant BTK degrader, which has demonstrated clinical activity in treating B-cell malignancies, including CNS lymphoma. The company focuses on translating scientific insights into innovative therapies for cancer and autoimmune diseases. Their commitment to developing a multi-modal portfolio positions them well in the competitive biopharma landscape.
Read more →NRIX▲ +26.7%on this newsshared move
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Read more →NRIX▲ +26.7%on this newsshared move
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Nurix Therapeutics presented evidence of clinical responses in two patients with B cell malignancies involving the CNS at the AACR 2024 Annual Meeting. The case studies included one patient with chronic lymphocytic leukemia (CLL) and another with primary central nervous system lymphoma (PCNSL), both showing significant responses to the BTK degrader NX-5948. Dr. Hansen emphasized the potential of NX-5948 for treating leukemias and lymphomas with CNS involvement. However, one patient exhibited disease progression despite prior positive outcomes, indicating ongoing challenges in treatment efficacy.
Read more →NRIXTargeting Degraders to the CNS for the Treatment of Cancer
Nurix is advancing its portfolio of therapies aimed at treating cancer and autoimmune diseases through novel scientific insights. The company emphasizes its dedication to developing breakthrough therapies and enhancing its protein degradation resources. This strategic focus positions Nurix to potentially outmatch current treatment options.
Read more →NRIXApproaches for DNA-Encoded Library Screening of Transcription Factors
Nurix is focused on developing breakthrough therapies by translating novel scientific insights. The company emphasizes its multi-modal portfolio of wholly owned and partnered assets aimed at combating cancer and autoimmune diseases. The article highlights their commitment to protein degradation resources.
Read more →NRIXNX-1607: a First-In-Class Inhibitor of Casitas B-lineage Lymphoma B (CBL-B) for Immuno-Oncology
Nurix is advancing NX-1607, a first-in-class inhibitor targeting CBL-B for immuno-oncology. This innovative approach aims to enhance treatment options for cancer and autoimmune diseases. The company emphasizes its dedication to developing breakthrough therapies through novel scientific insights.
Read more →NRIXNurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Read more →NRIXNurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
Nurix Therapeutics has been selected to join an international team of experts as part of the Cancer Grand Challenges initiative, focused on combating pediatric cancers through targeted protein degradation. The project, called KOODAC, aims to develop innovative oral therapies to treat solid tumors in children. This interdisciplinary collaboration involves ten institutions across several countries and seeks to target previously undruggable oncogenic fusion proteins. Burgeoning support, including a significant funding award, highlights Nurix's commitment to advancing cancer research and treatment.
Read more →NRIXFindings From the First-in-Human Phase 1 Trials of NX-2127 and NX-5948, Bruton’s Tyrosine Kinase (BTK) Degraders, in Patients with Relapsed/Refractory B-Cell Malignancies
Nurix has initiated first-in-human Phase 1 trials for NX-2127 and NX-5948, which are Bruton’s Tyrosine Kinase (BTK) degraders targeting relapsed/refractory B-cell malignancies. The trials aim to assess the safety and efficacy of these novel therapies. Further insights into the trials and their potential impact on cancer treatment are anticipated.
Read more →NRIXNurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
Nurix Therapeutics has unveiled NX-1607, the first CBL-B inhibitor, at the ACS Spring 2024 meeting. This inhibitor is designed to lock the CBL-B protein in an inactive state, enhancing T-cell activation in cancer treatment. Currently, NX-1607 is undergoing a Phase 1 trial, testing its safety and efficacy as both a monotherapy and in combination with paclitaxel in patients with various tumors. The results from the Phase 1a trial are anticipated in 2024, highlighting Nurix's innovative approach in drug discovery.
Read more →NRIXNurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
Read more →NRIXNurix logo Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial Nurix cleared to introduce new chirally controlled NX-2127 drug product and resume enrollment of new patients into the
Nurix Therapeutics announced that the FDA has lifted a partial clinical hold on its NX-2127 Phase 1 trial. This decision allows the company to resume patient enrollment using a new drug product manufactured through an improved process. The company aims to prioritize patients with aggressive types of non-Hodgkin’s lymphoma, which have previously demonstrated durable complete responses. Despite the positive news, there are inherent uncertainties related to clinical trials and the commercialization of their drug candidates.
Read more →NRIXNurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Nurix Therapeutics, Inc. announced that its Chief Scientific Officer, Dr. Gwenn M. Hansen, has been invited to present at the AACR 2024 Annual Meeting in San Diego. Dr. Hansen will feature NX-5948, a brain-penetrant BTK degrader currently in Phase 1 clinical trials for B cell malignancies. The event will showcase the significance of targeted protein modulation in treating cancer, with specific sessions dedicated to NX-5948's clinical activity.
Read more →NRIXA First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies
Nurix is initiating a first-in-human Phase 1 trial for NX-2127, a novel Bruton’s Tyrosine Kinase dual-targeted protein degrader. This trial aims to evaluate its efficacy in patients with relapsed or refractory B-cell malignancies. The approach represents a significant advancement in the treatment landscape for these challenging cancers.
Read more →NRIX▲ +6.9%on this news
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
Read more →NRIX▲ +6.9%on this news
Nurix logo Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update NX-5948 received fast track designation from the FDA NX-5948 showed positive results in Phase 1
Nurix Therapeutics reported strong financial results for Q4 and the fiscal year 2023, driven by a significant increase in revenue from partnerships. The company's candidate NX-5948 has received Fast Track designation from the FDA and demonstrated positive clinical results in a Phase 1 trial for treating chronic lymphocytic leukemia. However, the development of another candidate, NX-2127, faces delays due to a partial clinical hold. Nurix maintains a robust financial position, better positioning it for future growth.
Read more →NRIXNurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
Nurix Therapeutics has published findings in the journal Science regarding NX-2127, a novel BTK and IKZF1/3 degrader. The study reveals that certain BTK mutations, which typically confer resistance to established inhibitors, are still vulnerable to degradation by NX-2127. This innovative therapy has demonstrated therapeutic efficacy in patients with chronic lymphocytic leukemia, offering new hope for those with relapsed or refractory B-cell malignancies. The ongoing Phase 1 clinical trials also suggest the potential for broad applicability in treating various B-cell malignancies.
Read more →NRIXKinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127
Nurix is committed to developing innovative therapies targeting cancer and autoimmune diseases. Their approach involves a multi-modal portfolio that includes both wholly owned and partnered assets. The company is particularly focused on protein degradation as a promising avenue for treatment.
Read more →NRIXDiscovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
Nurix is advancing its research on NX-2127, an orally bioavailable degrader of Bruton’s Tyrosine Kinase. This compound shows promise for treating patients with B cell malignancies. The company aims to leverage novel scientific insights to develop breakthrough therapies targeting cancer and autoimmune diseases.
Read more →NRIX▼ -6.9%on this news
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
Nurix Therapeutics has received Fast Track designation from the U.S. FDA for its investigational drug NX-5948, aimed at treating relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The designation reflects the urgency of treatment for patients whose cancer has progressed after at least two prior therapies. Encouraging results from the ongoing Phase 1 trial show potential clinical benefits with good tolerability in patients. The designation may expedite the development process and enhance regulatory communication for Nurix as it seeks to advance NX-5948's clinical trials.
Read more →NRIXNurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases
Read more →NRIXImportant notice and disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigati
Nurix Therapeutics has released a presentation outlining their future plans and developments in targeted protein modulation. The company is focusing on the advancement of Degrader-Antibody Conjugates (DACs), which are expected to address resistance in cancer therapies. Additionally, they emphasize the significant market potential for their BTK degraders, which aim to provide new treatment options for patients. However, the presentation also highlights inherent uncertainties and risks related to clinical trials and regulatory approvals.
Read more →NRIXNurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics will present at the 42nd Annual J.P. Morgan Healthcare Conference, focusing on its achievements in 2023 and objectives for 2024. CEO Arthur T. Sands is scheduled to speak on January 8, 2024. The presentation will be available via live webcast and archived on the company's website. Nurix is known for its innovative approach to drug development, particularly in protein modulation for cancer treatment.
Read more →NRIXRole of Ternary Complex Formation and Ubiquitylation Assays in Early Protein Degrader Discovery
Nurix is focused on translating scientific insights into innovative therapies, particularly in the areas of cancer and autoimmune diseases. The article highlights their commitment to protein degradation research and provides access to related resources. However, specific details on the role of ternary complex formation and ubiquitylation assays are not elaborated.
Read more →NRIXASH Event Presentation 2023
Nurix is showcasing its commitment to developing innovative therapies at the ASH Event 2023. The company emphasizes its focus on translating scientific insights into effective treatments for cancer and autoimmune diseases. Their portfolio includes both wholly owned and partnered assets, highlighting a collaborative approach to drug development.
Read more →NRIXA First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including Diffuse Large B-Cell Lymphoma
Nurix is initiating a first-in-human Phase 1 trial of NX-1607, an oral CBL-B inhibitor, aimed at treating patients with advanced malignancies, including diffuse large B-cell lymphoma. This trial represents a significant step in the development of innovative cancer therapies. The company is committed to leveraging scientific insights for breakthrough treatments.
Read more →NRIXNurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting
Read more →NRIXNurix logo Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Positive
Nurix Therapeutics presented positive clinical trial data for its BTK degrader programs, NX-5948 and NX-2127, during the 65th American Society of Hematology Annual Meeting. Initial efficacy results indicate that NX-5948 shows promise in treating chronic lymphocytic leukemia, while NX-2127 demonstrated encouraging responses in non-Hodgkin lymphoma. Both drugs exhibited favorable safety profiles, though some treatment-related adverse events were reported. The company plans to continue development of both drug candidates, with ongoing clinical trials in multiple countries.
Read more →NRIX▲ +8.7%on this news· ran to +24% by day 3
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting
Read more →NRIXLeader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation November 2023 Important notice and disclaimers This presentation contains statements that relate to future eve
Nurix Therapeutics has presented its innovative strategies and drug development pipeline in its November 2023 investor presentation. The company focuses on targeted protein modulation and is advancing a range of drug candidates for cancer and autoimmune diseases, including collaborations with Gilead and Sanofi. However, the presentation highlights inherent risks related to drug approvals, clinical trial outcomes, and macroeconomic uncertainties that could impact their future performance.
Read more →NRIXNurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting
Read more →NRIXNX-1607, a small molecule inhibitor of CBL-B, enhances anti-PD-1-mediated tumor growth inhibition by reshaping intratumoral innate and adaptive immune responses
Nurix is focused on developing innovative therapies for cancer and autoimmune diseases. Their approach involves leveraging novel scientific insights to enhance treatment efficacy. The article highlights their commitment to advancing a diverse portfolio of assets, including NX-1607, a small molecule inhibitor aimed at improving anti-PD-1-mediated tumor growth inhibition.
Read more →NRIXNurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial Currently enrolled patients may continue receiving NX-2127
Nurix Therapeutics announced a partial clinical hold on its Phase 1 trial for NX-2127, affecting new patient enrollment. While this pause is in effect, currently enrolled patients who are benefiting from the treatment may continue. The hold was prompted by Nurix's plans to transition to an improved manufacturing process for NX-2127, although other drug programs remain unaffected. The company is actively working with the FDA to resolve the issue promptly.
Read more →NRIX▲ +6.3%on this news· ran to +23% by day 3shared move
Overcoming Acquired Inhibitor Resistance & Addressing Novel Scaffolding Functions of BTK in the Clinic
Nurix is focused on developing innovative therapies to combat cancer and autoimmune diseases. The company emphasizes the importance of novel scientific insights and has a multi-modal portfolio of assets. Their approach includes addressing challenges related to acquired inhibitor resistance and exploring new functions of BTK in clinical settings.
Read more →NRIX▼ -8.6%on this news
Roy Baynes, MB.Bch., M.Med., Ph.D.
Roy Baynes, MB.Bch., M.Med., Ph.D., has been a member of Nurix's Medical Advisory Board since 2023. He is currently the Chief Medical Officer at Eikon Therapeutics and has a notable history at Merck & Co., where he oversaw the development of numerous significant medicines. His extensive background in oncology and internal medicine positions him as a valuable asset in the biopharma sector.
Read more →NRIX▼ -8.6%on this newsshared move
Ronald Levy, M.D.
Dr. Ronald Levy has joined Nurix's Medical Advisory Board in 2023. He is a prominent figure in lymphoma research and has a notable history of developing monoclonal antibodies, including rituximab. His expertise in immunology and molecular biology will contribute significantly to Nurix's initiatives in cancer treatment.
Read more →NRIX▼ -6%on this news
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced strategic collaboration with Seagen to develop a portfolio of Degrader-Antibody Conjugates, resulting in a
Nurix Therapeutics reported strong financial results for the third quarter of fiscal 2023, reflecting significant collaboration revenues including a $60 million payment from Seagen for developing Degrader-Antibody Conjugates. The company maintained a robust financial position with cash reserves expected to fund operations into 2025. Although net losses remain considerable at $37 million, progress in trial expansions for several of its drug candidates indicates positive momentum in their clinical pipeline.
Read more →NRIXNX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Nurix is making strides in developing therapies that target a wide range of BTK mutants, which are known to resist traditional inhibitors and other degraders. Their focus on protein degradation aims to provide innovative solutions for cancer and autoimmune diseases. The company emphasizes its commitment to translating scientific insights into effective treatments.
Read more →NRIXNX-2127: A Degrader of BTK and IKZF1/3
Nurix is committed to developing innovative therapies through its multi-modal portfolio. The company focuses on translating scientific insights into effective treatments for cancer and autoimmune diseases. Their approach includes the use of protein degradation resources to enhance therapeutic outcomes.
Read more →NRIXTargeting a Novel E3 Ligase with a Small Molecule Inhibitor
Nurix is advancing its portfolio of therapies aimed at cancer and autoimmune diseases. The company is dedicated to translating scientific insights into effective treatments. Their focus includes novel approaches such as targeting E3 ligases with small molecule inhibitors.
Read more →NRIXTargeted Protein Degradation of BTK Overcomes Clinically-Relevant Resistance Mutations and Its Oncogenic Scaffolding Functions
Nurix is advancing its portfolio focused on targeted protein degradation, particularly concerning BTK, to address resistance mutations in cancer therapies. The company aims to translate scientific insights into effective treatments for cancer and autoimmune diseases. Their approach highlights the potential of novel therapies in overcoming challenges faced in current treatments.
Read more →NRIXNX-1607, a small molecule inhibitor of CBL-B, is efficacious as a single agent and in combination with Rituximab in preclinical mouse models of lymphoma
Nurix has reported that NX-1607, a small molecule inhibitor of CBL-B, demonstrates efficacy both as a standalone treatment and in combination with Rituximab in preclinical models of lymphoma. This advancement highlights the potential of NX-1607 in targeting cancer and autoimmune diseases. The results from mouse models suggest a significant therapeutic promise.
Read more →NRIXTargeted Protein Degraders for the Treatment of Hematologic Malignancies: Addressing the Mutational Resistance of BTK in the Clinic
Nurix is advancing its portfolio of therapies aimed at treating hematologic malignancies, particularly focusing on overcoming mutational resistance in BTK. The company emphasizes its commitment to translating scientific insights into effective treatments for cancer and autoimmune diseases. Their resources on protein degradation are available for further exploration.
Read more →NRIX▲ +8.3%on this news
Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics
Nurix Therapeutics has announced a strategic collaboration with Seagen to develop Degrader-Antibody Conjugates (DACs), an innovative approach combining antibody-drug conjugation and targeted protein degradation. The deal includes an upfront payment of $60 million and potential milestone payments totaling approximately $3.4 billion, along with future royalties. Nurix will utilize its DELigase platform to create targeted protein degraders, while Seagen will handle the conjugation and development of these new therapeutic candidates. This partnership aims to enhance the efficacy and safety of cancer treatment options.
Read more →NRIXFirst Disclosure of NX-5948, an Oral Targeted Degrader of Bruton’s Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies
Nurix has disclosed NX-5948, an oral targeted degrader of Bruton’s Tyrosine Kinase (BTK), aimed at treating B-cell malignancies. This development is part of Nurix's broader strategy to advance innovative therapies for cancer and autoimmune diseases. The company emphasizes its commitment to translating scientific insights into effective treatments.
Read more →NRIXTargeted Protein Degradation for Treatment of Hematologic Malignancies Addressing Both the Enzymatic and Scaffolding Functions of BTK Using NX-5948 and NX-2127 in the Clinic
Nurix is advancing its multi-modal portfolio aimed at treating hematologic malignancies through targeted protein degradation. The company is focusing on the dual functions of BTK, utilizing NX-5948 and NX-2127 in clinical settings. This approach aims to provide innovative therapies for cancer and autoimmune diseases.
Read more →NRIXNurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin's lymphomas Presented data highlighting the potent c
Nurix Therapeutics reported its financial results for the second quarter of fiscal 2023, highlighting significant revenue growth driven by a licensing agreement with Gilead. The company announced the expansion of Phase 1b cohorts for its drug NX-2127 in the treatment of non-Hodgkin's lymphoma, backed by promising clinical data. Despite the positive developments, Nurix faced a net loss of $24.3 million in the quarter, alongside increasing operational costs. Overall, the firm maintains a strong financial position with $308.6 million in cash and marketable securities.
Read more →NRIXNurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Nurix Therapeutics announced the initiation of Phase 1b expansion trials for NX-2127 in patients with diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), backed by positive clinical data showing sustained response. Additionally, NX-5948 shows rapid and robust BTK degradation, demonstrating efficacy in preclinical models, including central nervous system lymphoma. The company aims to address treatment resistance in B cell malignancies with these targeted protein degraders, and updates from both programs are expected in the latter half of 2023.
Read more →NRIX▲ +5.2%on this news
Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
Nurix Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 2023 RBC Capital Markets Global Healthcare Conference, scheduled for May 17. Arthur T. Sands, M.D., Ph.D., CEO of Nurix, will engage in a fireside chat during the event. Nurix specializes in developing targeted protein modulation drugs for hematologic malignancies and solid tumors, leveraging their integrated discovery platform, DELigase, to advance novel therapeutic candidates.
Read more →NRIX▲ +8.7%on this news
Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations
Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations
Read more →NRIX▲ +12.4%on this news· ran to +36% by day 1shared move
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Licensed to Gilead a new development candidate, NX-0479 GS-6791, a targeted protein degrader of IRAK4, resulting in a
Nurix Therapeutics recently announced its financial results for the first quarter of fiscal 2023 and reported significant progress in its collaborations, particularly with Gilead, which licensed NRIX's targeted protein degrader NX-0479 GS-6791. This licensing deal generated a $20 million payment and additional milestone payments could total up to $425 million. Despite the positive developments, Nurix reported a net loss of $40.7 million for the quarter, although its financial position remains strong with over $325 million in cash and marketable securities.
Read more →NRIXNurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Nurix Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 20. CEO Arthur T. Sands will engage in a fireside chat, highlighting the company’s innovative drug development strategies. Nurix focuses on targeted protein modulation therapies for both hematologic malignancies and solid tumors. The event will be accessible via a live webcast, and an archived version will be available for 30 days post-event.
Read more →NRIXNurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Read more →NRIXNurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14. The company's president and CEO, Arthur T. Sands, M.D., Ph.D., will provide an overview of their innovative approaches to treating hematologic malignancies and solid tumors. The event will feature a live webcast, and the archived presentation will be available for 30 days afterward. Nurix Therapeutics specializes in targeted protein modulation, leveraging their integrated discovery platform for novel drug development.
Read more →NRIXNurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients
Nurix Therapeutics has reported positive financial results for the fourth quarter and fiscal year 2022, highlighting significant achievements in its drug development pipeline. Notably, NX-2127 has shown the ability to overcome BTK inhibitor resistance mutations, providing clinical benefits to CLL patients with unmet needs. The company also reported a strong cash position of $373 million and anticipates further progress with ongoing clinical trials in 2023. Milestones achieved in collaborations with Gilead Sciences and Sanofi were also outlined, indicating a commitment to expanding their therapeutic offerings.
Read more →NRIX▼ -6.4%on this news
Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation January 2023 Important Notice and Disclaimers This presentation contains statements that relate to future even
Nurix Therapeutics presented a forward-looking overview of its business and clinical development strategies in January 2023. The presentation highlighted the company's exciting advances in targeted protein modulation therapies, specifically their ongoing clinical programs for B-cell malignancies. Key developments include positive clinical activities demonstrated by their BTK degraders, NX-2127 and NX-5948, which address treatment resistance in chronic lymphocytic leukemia (CLL) and other cancers. Despite these advancements, the company cautioned investors about the inherent risks in drug development and external market pressures that could affect outcomes.
Read more →NRIX▼ -6.4%on this news
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities
Read more →NRIXNurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
Read more →NRIXNurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
NX-5948 is being evaluated in patients with relapsed and refractory B-cell malignancies Phase 1 clinical trial now enrolling patients in the United Kingdom with plans to expand to clinical sites in the United States SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Nurix Therape
Read more →NRIXNurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64 th American Society of Hematology (ASH) Annual Meeting Treatment with NX-2127 provides clinically meaningful responses
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) pa
Read more →NRIXNurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting
SAN FRANCISCO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it wil
Read more →NRIX▲ +14.4%on this news
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies
Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond to levels associated with potent anti-tumor activity in disease models SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEW
Read more →NRIX▲ +14.4%on this news
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in
SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented preclinical data
Read more →NRIXNurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
Read more →NRIXLeader in Targeted Protein Modulation The First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic Arthur T. Sands, M.D., Ph.D. President & CEO 5th Annual TPD Summit Boston, MA October 26th, 2022 1 Imp
Degraders in Hematologic Malignancies: The Latest from the Clinic Arthur T. Sands, M.D., Ph.D. President & CEO 5th Annual TPD Summit Boston, MA October 26th, 2022 1 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectati
Read more →NRIXNurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin's Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin's Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit
Read more →NRIX▼ -5.1%on this news
Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it will make several presentations, including a Keynote Plenary presentation by
Read more →NRIX▼ -6.5%on this news
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial p
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial position with $413.6 million in cash and marketable securit
Read more →NRIX▼ -5.1%on this news· ran to -17% by day 3shared move
Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting
Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting
Read more →NRIXNurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors
Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors SAN FRANCISCO, September 14, 2022 Nurix Therapeutics , Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announ
Read more →NRIX▲ +9.5%on this news
Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Eric Schlezinger, J.D. has joined the company as chief people officer. Mr. Schle
Read more →NRIX▲ +14.5%on this news
Nurix Therapeutics Announces $40 Million Registered Direct Offering
Nurix Therapeutics Announces $40 Million Registered Direct Offering
Read more →NRIX▲ +7.2%on this news· ran to +23% by day 1shared move
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-594
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-5948 Phase 1a clinical trial for certain B-cell malignancies
Read more →NRIX▲ +7.2%on this news· ran to +23% by day 1shared move
Nurix Therapeutics Announces $55 Million Registered Direct Offering
Nurix Therapeutics Announces $55 Million Registered Direct Offering SAN FRANCISCO, July 7, 2022 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securitie
Read more →NRIXNurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enrolling patients in U.K. with plans to expand to clinical sites in the U.S. SAN FRANCISCO, June 30, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutic
Read more →NRIX▼ -7.6%on this news
Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress
SAN FRANCISCO, June 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-own
Read more →NRIX▲ +16.3%on this news· ran to +30% by day 3
Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Read more →NRIX▼ -22.7%on this news
Nurix Therapeutics Announces Initiation of Phase 1b Expansion Cohorts in Ongoing Phase 1 Trial of NX-2127
Nurix Therapeutics Announces Initiation of Phase 1b Expansion Cohorts in Ongoing Phase 1 Trial of NX-2127
Read more →NRIX▼ -22.7%on this news
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase
Read more →NRIX▼ -22.7%on this news
Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine R&D Day New York, NY
Blazing a New Path in Medicine R&D Day New York, NY May 26, 2022 Welcome and Introduction Arthur T Sands, MD, PhD President, CEO and Board Director Nurix Therapeutics 2 Important Notice and Disclaimers This presentation contains statements that relate to future events and exp
Read more →NRIX▲ +7.7%on this news
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas
SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1a/1b study to evaluate orally avai
Read more →NRIXNurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will
Read more →NRIX▼ -8.6%on this newsshared move
Nurix Therapeutics to Host R&D Day on May 26, 2022
SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced it will host a research & development (R&D) day for analysts and investors that will b
Read more →NRIX▲ +11.8%on this news
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting
Read more →NRIXNurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix's drug-enhanced tumor infiltrating lymphocyte (TIL) pro
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix's drug-enhanced tumor infiltrating lymphocyte (TIL) program Awarded Innovation Passport for Entry into Innovative
Read more →NRIXNurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors
Read more →NRIXNurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, wi
Read more →NRIX▲ +8.9%on this news
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases SAN FRA
Read more →NRIXNurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting
Read more →NRIX▼ -6%on this news
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate i
Read more →NRIX▼ -6.6%on this news
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update Advanced four wholly owned and internally developed programs into clinical development Strengthened balance
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update Advanced four wholly owned and internally developed programs into clinical development Strengthened balance sheet with year-end cash and investments totaling $433 mi
Read more →NRIX▼ -15.9%on this news
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
Read more →NRIX▼ -15.9%on this news
Important Notice and Disclaimers This presentation contains information relating to Nurix Therapeutics, Inc. (the "Company," "we," "us" or "our") and forward-looking statements within the meaning of the "safe harbor" pro
Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation January 2022 Exhibit 99.1 Important Notice and Disclaimers This presentation contains information relating to Nurix Therapeutics, Inc. (the "Company," "we," "us" or "our") and forward-looking statements wi
Read more →NRIXNurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix will present an ov
Read more →NRIXNurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting
Read more →NRIXNurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targ
Read more →NRIXNurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular therapy officer, is awarded Lifetime Achievement award by SITC at its annual meeting
Read more →NRIX▲ +17.3%on this news
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of mechanism of targeted protein degradation in patients with hematologic malignancies Nur
Read more →NRIXNurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit
Presentation to include initial pharmacokinetic and BTK degradation data Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021 SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developi
Read more →NRIXNurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix’s president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurix’s chief s
Read more →NRIXNurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer Expanded Board of D
Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer Expanded Board of Directors with experienced business leaders Strong financi
Read more →NRIXNurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders
Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders SAN FRANCISCO, September 30, 2021 (GLOBE NEWSWIRE) Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the
Read more →NRIXNurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three additional wholly ow
Read more →NRIXNurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development
SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president
Read more →NRIXNurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease Orally available NX-5948 is a potent selective degra
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease Orally available NX-5948 is a potent selective degrader of Bruton s Tyrosine Kinase (BTK) without IMiD activi
Read more →NRIXNurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors
Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its June 1, 2021 (GLOBE NEWSWIRE) Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its
Read more →NRIXNurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
Read more →NRIXNurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resul
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong fin
Read more →NRIXNurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a fireside
Read more →NRIXNurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8 Initiative SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeut
Read more →NRIXNurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR
Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR
Read more →NRIXNurix Therapeutics to Participate and Present at Upcoming Investor Conferences
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate and present at th
Read more →NRIXNurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public
Read more →NRIXNurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Read more →NRIXNurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock
SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All
Read more →NRIXNurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refracto
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies Three additional wholly owned progr
Read more →NRIXNurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies
Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies
Read more →NRIXNurix Therapeutics Announces Presentation at 39th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will present a corporate overview a
Read more →NRIXDisclosures All authors of this presentation are current or former employees and shareholders of Nurix Therapeutics. Nurix Therapeutics. All rights reserved. NX-2127 has a dual degradation mechanism of action for two cli
NX-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies Presenter: Daniel Robbins, Ph. D. drobbins@nurixtx.com Exhibit 99.1 Disclosures All authors of this NX-2127 has a dual degradation malignancies Mutations to BTK have conferred resistan
Read more →NRIXNurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of key preclinical data from its lead program, NX-2127, for the potential treatment
Read more →NRIXNurix Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be presenting at the following healthcare investor conferences: Stifel 2020 Virtual He
Read more →NRIXNurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 62nd ASH Annual Meeting and Exposition
SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present data on its novel targeted protein degradation platform at the upcoming 5th Med
Read more →NRIXNurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors
Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors SAN FRANCISCO, Oct. 26, 2020 (GLOBAL NEWSWIRE) Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to
Read more →NRIXNurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update Completed recent IPO raising approximately $238.5 million in gross proceeds On track for multiple IND filings San Fra
Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update Completed recent IPO raising approximately $238.5 million in gross proceeds On track for multiple IND filings San Francisco, CA, October 14, 2020 -- Nurix Therapeutics Inc. (
Read more →NRIXImportant Notice and Disclaimers This presentation contains forward-looking statements and information relating to Nurix Therapeutics, Inc. (the "Company," "we," "us" or "our"). Forward-looking statements are neither his
Nurix Therapeutics Blazing a New Path in Medicine Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels TPD Conference 2020 Exhibit 99.1 Important Notice and Disclaimers This presentation contains forward-looking statements and
Read more →NRIXNurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit
Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit
Read more →NRIXNurix Therapeutics Announces Pricing of $209 Million Initial Public Offering
Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering
Read more →NRIXNurix Therapeutics Announces Addition of Dr. Jason Kantor to its Management Team
SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Jason Kantor as senior vice president, finance and investment strategy. In this role, Dr. Kantor will be respo
Read more →NRIXNurix Therapeutics Announces Formation of DeCART Therapeutics to Advance New CAR T Therapies Using Targeted Protein Modulation
SAN FRANCISCO, June 25, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidia
Read more →NRIXNurix Therapeutics Announces Addition of Immuno-Oncology Clinical Experts to its Management Team
Nurix Therapeutics Announces Addition of Immuno-Oncology Clinical Experts to its Management Team
Read more →NRIXNurix Therapeutics Closes $120 Million Financing to Advance Targeted Protein Modulation Drug Pipeline
Nurix Therapeutics Closes $120 Million Financing to Advance Targeted Protein Modulation Drug Pipeline
Read more →NRIXNurix Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
SAN FRANCISCO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced that CEO Arthur Sands will present at the Cowen & Co. 40th Annual Health Care Conference on Wednesday, March 4, 2020, 3:30 PM ET in B
Read more →NRIXNurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies
SAN FRANCISCO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company researching novel therapies that control degradation of disease-causing proteins, today announced a global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of
Read more →NRIXNurix Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs announced today that CEO Arthur Sands will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 8:30 a.m. PST
Read more →NRIXNurix Therapeutics Announces Scientific Presentations on its BTK Program at the 61st American Society of Hematology Annual Meeting
SAN FRANCISCO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing novel therapies that control disease-causing proteins, today announced an oral presentation on its wholly-owned, BTK degrader program for chronic lymphocytic leukemia will be delivered
Read more →NRIXNurix Therapeutics Announces Key Management Additions
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced the appointment of Dr. Christine Ring as the company’s general counsel, Dr. Cristiana Guiducci as vice president of imm
Read more →NRIXNurix Therapeutics Announces Upcoming Investor Conference Schedule
SAN FRANCISCO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that the Company management team will attend the Stifel 2019 Healthcare conference and the 31st Annual Piper Jaffray He
Read more →NRIXNurix Therapeutics Announces Upcoming Scientific Presentation for its CBL-B Program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
SAN FRANCISCO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that it will present data on its wholly-owned, CBL-B small molecule drug development program at the Society for Immunot
Read more →NRIXNurix Therapeutics to Present at the Targeted Protein Degradation Summit 2019
SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that Arthur Sands, M.D., Ph.D., chief executive officer, and Gwenn Hansen, Ph.D., senior vice president, research, will
Read more →NRIXNurix Therapeutics Announces Key Additions to its Board of Directors
SAN FRANCISCO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced Lori A. Kunkel, M.D., and Julia Gregory have joined its board of directors. In addition, David
Read more →NRIXNurix Therapeutics to Present at the Needham & Company 18th Annual Healthcare Conference
SAN FRANCISCO, April 04, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a private company discovering drugs that harness the body’s natural process to control protein levels, today announced that Arthur Sands, M.D., Ph.D., chief executive officer, will present at the Needham
Read more →NRIXNurix Therapeutics to Present at 2019 American Association for Cancer Research (AACR) Annual Meeting
SAN FRANCISCO, March 19, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a private company discovering drugs that harness the body’s natural process to control protein levels, today announced an upcoming oral presentation at the 2019 American Association for Cancer Research (A
Read more →NRIXNurix Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
SAN FRANCISCO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a private company discovering drugs that harness the body’s natural process to control protein levels, today announced that Arthur Sands, M.D., Ph.D., chief executive officer, will present at the 30th Annu
Read more →NRIXNurix Therapeutics to Present at the Stifel Healthcare Conference
SAN FRANCISCO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a private company discovering drugs that harness the body’s natural process to control protein levels, today announced that Arthur Sands, M.D., Ph.D., chief executive officer, will present at the Stifel He
Read more →NRIXNurix Therapeutics to Present at the Targeted Protein Degradation Summit 2018
SAN FRANCISCO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a private company discovering drugs that harness the body’s natural process to control protein levels, today announced that Arthur Sands, M.D., Ph.D., chief executive officer, will present at the Targeted
Read more →NRIXNurix Therapeutics to Present at the 2018 BIO Investor Forum
SAN FRANCISCO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a private company discovering drugs that harness the body’s natural process to control protein levels, today announced that Arthur Sands, M.D., Ph.D., chief executive officer, will present at the 2018 BIO
Read more →NRIXNurix Appoints Nancy Pryer, Ph.D., Chief Development Officer
SAN FRANCISCO, May 08, 2018 (GLOBE NEWSWIRE) -- Nurix, Inc., a private drug discovery company, today announced the appointment of Dr. Nancy Pryer as the company’s chief development officer. Dr. Pryer will join Nurix’s executive management team to lead the company’s preclinical, t
Read more →Competitive Position
How NRIX ranks across every disease it competes inCompetitive Position is a premium feature
See how NRIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial